Legend Biotech (LEGN) Non-Current Deffered Revenue (2019 - 2025)
Legend Biotech's (LEGN) quarterly Non-Current Deffered Revenue came in at -$277000.0 in Q2 2025, down 110.24% YoY from $2.7 million in Q2 2024, and down 106.72% on a QoQ basis from -$134000.0 in Q1 2025.
Legend Biotech (LEGN) Non-Current Deffered Revenue (2019 - 2025) Analysis & Trends
Legend Biotech (LEGN) has 7 years of Non-Current Deffered Revenue data on file, last reported at -$277000.0 in Q2 2025.
- Quarterly Non-Current Deffered Revenue fell 110.24% year-over-year to -$277000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$277000.0 (down 110.24% YoY) and the FY2023 annual result came in at $48.0 million, up 15722.8% from the prior year.
- Non-Current Deffered Revenue retreated to -$277000.0 in Q2 2025, from -$134000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $252.6 million in Q2 2021 to a low of -$484000.0 in Q3 2023.
- A 5-year average of $23.2 million and a median of -$145000.0 in 2022 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue sank 158.77% — and 2023, when it jumped 62388.31%.
- Tracing LEGN's Non-Current Deffered Revenue over 5 years: stood at -$295000.0 in 2021, then advanced by 20.68% to -$234000.0 in 2022, then surged by 20596.58% to $48.0 million in 2023, then slumped by 100.9% to -$430000.0 in 2024, then surged by 35.58% to -$277000.0 in 2025.
- The last three Non-Current Deffered Revenue figures came in at -$277000.0 (Q2 2025), -$134000.0 (Q1 2025), and -$430000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -277,000.00 |
| Mar 31, 2025 | -134,000.00 |
| Sep 30, 2024 | -430,000.00 |
| Jun 30, 2024 | 2.70 Mn |
| Mar 31, 2024 | 23.11 Mn |
| Dec 31, 2023 | 47.96 Mn |
| Sep 30, 2023 | -484,000.00 |
| Jun 30, 2023 | -360,000.00 |
| Mar 31, 2023 | 47.96 Mn |
| Sep 30, 2022 | -234,000.00 |
| Jun 30, 2022 | -156,000.00 |
| Mar 31, 2022 | -77,000.00 |
| Dec 31, 2021 | -295,000.00 |
| Sep 30, 2021 | -219,000.00 |
| Jun 30, 2021 | 252.63 Mn |
| Mar 31, 2021 | -71,000.00 |
| Dec 31, 2020 | -114,000.00 |
| Dec 31, 2019 | 277.77 Mn |